Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [Breast Cancer Res Treat, (2014), 143, (325-332), 10.1007/s10549-013-2810-9];A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure

Breast Cancer Research and Treatment

Volumn 143, Issue 2, 2014, Pages 325-332

  Massarweh, Suleiman ^a,b   Romond, Edward ^a,b   Black, Esther P ^b   Van Meter, Emily ^b   Shelton, Brent ^b   Kadamyan Melkumian, Vera ^b   Stevens, Mark ^b   Elledge, Richard ^c,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d San Antonio Cancer Institute   (United States)

Author keywords

Breast cancer; Endocrine resistance; Estrogen receptor; Everolimus; Fulvestrant; MTOR

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ASPARTATE AMINOTRANSFERASE; EVEROLIMUS; FULVESTRANT; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; ESTROGEN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ACUTE CHOLECYSTITIS; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; BREAST BIOPSY; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; EDEMA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEMALE; HEART VENTRICLE THROMBOSIS; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LOADING DRUG DOSE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RASH; SKIN DISEASE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT FAILURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT FAILURE;

EID: 84893646332     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3263-0     Document Type: Erratum

References (32)

1. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247-2258. doi: 10.1002/1097-0142(20011101)92:9<2247: AID-CNCR1570>3.0.CO;2-Y
2. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19(10):2596-2606
3. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JPA (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98(18):1285-1291. doi: 10.1093/jnci/djj357
4. Osborne C, Wakeling A, Nicholson R (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1):S2-S6
5. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664-1670. doi: 10.1200/JCO.2007.13.5822
6. Massarweh S, Schiff R (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13(Supplement 1):S15-S24. doi: 10.1677/erc.1.01273
7. Leary A, Sirohi B, Johnston S (2007) Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Res 9(5):112
8. Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A (2007) Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 13(9):2751-2757. doi: 10.1158/1078-0432.ccr-06-2466
9. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J Jr, Berstein L, Yue W (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12(Supplement 1):S61-S73. doi: 10.1677/erc.1.01018
10. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ (2001) Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61(16):5985-5991
11. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA (2007) Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18(8):1323-1328. doi: 10.1093/annonc/mdm170
12. Treeck O, Wackwitz B, Haus U, Ortmann O (2006) Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102(2):292-299
13. Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29(33):4452-4461. doi: 10.1200/jco.2010.34.4879
14. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70. doi: 10.1038/nature11412
15. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo W-L, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung M-C, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084-6091. doi: 10.1158/0008-5472.can-07-6854
16. Bachelot T (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO Study. J Clin Oncol 30:2718-2724
17. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520-529. doi: 10.1056/NEJMoa1109653
18. Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, Audeh MW, Alencar VM, Lombard J, Mookerjee B, Xu J, Brown K, Klein P (2013) Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs 31(5):1345-1354. doi: 10.1007/s10637-013-9991-2
19. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA (2013) N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol 24(10):2548-2554
20. Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL, Kaufman PA (2013) Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 14(3):228-235. doi: 10.1016/S1470-2045(13)70026-3
21. Burstein HJ, Barry WT, Cirrincione C, Chew HK, Tolaney S, Lake D, Pluard T, Blackwell K, Winer EP, Hudis CA (2010) Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: a double-blinded, placebo-controlled, randomized phase III study. Cancer Res 70(24 Suppl 2):Abstr nr PD-05-01. doi: 10.1158/0008-5472.SABCS10-PD05-01
22. Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve SS, Sledge GW (2012) A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 133(3):1049-1056. doi: 10.1007/s10549-012-1997-5
23. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87(10):746-750
24. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22(9):1605-1613. doi: 10.1200/JCO.2004.02.112
25. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20(16):3396-3403
26. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386-3395
27. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JPO, Sapunar F, Martin M (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg With fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594-4600. doi: 10.1200/jco.2010.28.8415
28. Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14(10):989-998. doi: 10.1016/S1470-2045(13)70322-X
29. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367(5):435-444. doi: 10.1056/NEJMoa1201622
30. Bergh J, Jönsson P-E, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, Lindemann JPO, Wiklund F, Henriksson R (2012) FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30(16):1919-1925. doi: 10.1200/jco.2011.38.1095
31. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF (2012) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. doi: 10.1200/jco.2011.38.3331
32. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30(23):2919-2928. doi: 10.1200/JCO.2011.39.7356